Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer

Sanda, 2018, Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part I. Risk stratification, shared decision making, and care options, J Urol, 199, 683, 10.1016/j.juro.2017.11.095 Chen, 2016, Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement, J Clin Oncol, 34, 2182, 10.1200/JCO.2015.65.7759 Yamamoto, 2016, Metastatic prostate cancer in men initially treated with active surveillance, J Urol, 195, 1409, 10.1016/j.juro.2015.11.075 Hamdy, 2016, 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220 Tosoian, 2015, Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer, J Clin Oncol, 33, 3379, 10.1200/JCO.2015.62.5764 Sundi, 2015, Reclassification rates are higher among African American men than Caucasians on active surveillance, Urology, 85, 155, 10.1016/j.urology.2014.08.014 Telang, 2017, Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature, BJU Int, 120, 464, 10.1111/bju.13862 Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882 Mateo, 2017, DNA repair in prostate cancer: Biology and clinical implications, Eur Urol, 71, 417, 10.1016/j.eururo.2016.08.037 Na, 2017, Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death, Eur Urol, 71, 740, 10.1016/j.eururo.2016.11.033 Pearce, 2015, A longitudinal study of predictors of sexual dysfunction in men on active surveillance for prostate cancer, Sex Med, 3, 156, 10.1002/sm2.78 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 162, 454, 10.1016/j.cell.2015.06.053 Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144 Li, 2009, Fast and accurate short read alignment with Burrows-Wheeler transform, Bioinformatics, 25, 1754, 10.1093/bioinformatics/btp324 Stenson, 2003, Human Gene Mutation Database (HGMD): 2003 update, Hum Mutat, 21, 577, 10.1002/humu.10212 Landrum, 2014, ClinVar: public archive of relationships among sequence variation and human phenotype, Nucleic Acids Res, 42, D980, 10.1093/nar/gkt1113 Green, 2013, ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing, Genet Med, 15, 565, 10.1038/gim.2013.73 Southern, 2006, Kaplan-Meier methods yielded misleading results in competing risk scenarios, J Clin Epidemiol, 59, 1110, 10.1016/j.jclinepi.2006.07.002 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Alexander, 2009, Fast model-based estimation of ancestry in unrelated individuals, Genome Res, 19, 1655, 10.1101/gr.094052.109 Giri, 2018, Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017, J Clin Oncol, 36, 414, 10.1200/JCO.2017.74.1173 Edwards, 2003, Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene, Am J Hum Genet, 72, 1, 10.1086/345310 Mateo, 2018, Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study, Eur Urol, 73, 687, 10.1016/j.eururo.2018.01.010